

NEUROSCIENTIFIC RECEIVES \$2.2 MILLION R&D TAX INCENTIVE REFUND

NeuroScientific Biopharmaceuticals Ltd (**ASX:NSB**) (“**NeuroScientific**” or “**the Company**”) is pleased to advise that it has received an R&D tax incentive refund of \$2,211,829, from its research and development (R&D) tax incentive claim for the 2022/2023 financial year.

The R&D tax incentive program is an Australian Government program under which companies receive cash refunds of 18.5% above the Company’s marginal tax rate (totalling 48.5% for NSB), for eligible expenditure on research and development.

NeuroScientific Chairman, Chris Ntoumenopoulos said, “We are sincerely grateful for the Australian Federal Government’s support of Australian research and development. This refund strengthens NeuroScientific’s financial position as we continue our R&D programs in support of EmtinB, a novel, peptide-based drug that targets neurodegenerative conditions such as glaucoma.”

This announcement is authorised by the board of NeuroScientific Biopharmaceuticals Ltd.

-ENDS-

For more information please contact:

Chris Ntoumenopoulos
Chairman
ir@neuroscientific.com
+ 61 8 6382 1805